vs
CATHAY GENERAL BANCORP（CATY）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
CATHAY GENERAL BANCORP的季度营收约是再鼎医药的1.8倍（$222.8M vs $127.1M），CATHAY GENERAL BANCORP同比增速更快（19.5% vs 17.1%），CATHAY GENERAL BANCORP自由现金流更多（$363.7M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 12.8%）
国泰万通金控是总部位于美国的银行控股公司，旗下运营国泰银行，面向亚裔社区、中小企业提供个人及商业存贷款、财富管理等金融服务，业务覆盖加州、纽约、得州等美国多州及部分亚洲市场。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
CATY vs ZLAB — 直观对比
营收规模更大
CATY
是对方的1.8倍
$127.1M
营收增速更快
CATY
高出2.4%
17.1%
自由现金流更多
CATY
多$390.4M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
12.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $222.8M | $127.1M |
| 净利润 | $90.5M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 50.9% | -54.6% |
| 净利率 | 653.4% | — |
| 营收同比 | 19.5% | 17.1% |
| 净利润同比 | 12.9% | — |
| 每股收益（稀释后） | $1.33 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CATYZLAB
| Q4 25 | $222.8M | $127.1M | ||
| Q3 25 | $210.6M | $115.4M | ||
| Q2 25 | $196.6M | $109.1M | ||
| Q1 25 | $187.8M | $105.7M | ||
| Q4 24 | $186.5M | $108.5M | ||
| Q3 24 | $189.5M | $101.8M | ||
| Q2 24 | $178.5M | $100.1M | ||
| Q1 24 | $175.2M | $87.1M |
净利润CATYZLAB
| Q4 25 | $90.5M | — | ||
| Q3 25 | $77.7M | $-36.0M | ||
| Q2 25 | $77.5M | $-40.7M | ||
| Q1 25 | $69.5M | $-48.4M | ||
| Q4 24 | $80.2M | — | ||
| Q3 24 | $67.5M | $-41.7M | ||
| Q2 24 | $66.8M | $-80.3M | ||
| Q1 24 | $71.4M | $-53.5M |
毛利率CATYZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率CATYZLAB
| Q4 25 | 50.9% | -54.6% | ||
| Q3 25 | 44.5% | -42.3% | ||
| Q2 25 | 49.0% | -50.3% | ||
| Q1 25 | 46.1% | -53.3% | ||
| Q4 24 | 46.5% | -62.6% | ||
| Q3 24 | 41.2% | -66.6% | ||
| Q2 24 | 40.7% | -76.0% | ||
| Q1 24 | 45.7% | -80.7% |
净利率CATYZLAB
| Q4 25 | 653.4% | — | ||
| Q3 25 | 36.9% | -31.2% | ||
| Q2 25 | 39.4% | -37.3% | ||
| Q1 25 | 37.0% | -45.8% | ||
| Q4 24 | 587.9% | — | ||
| Q3 24 | 35.6% | -40.9% | ||
| Q2 24 | 37.4% | -80.2% | ||
| Q1 24 | 40.8% | -61.4% |
每股收益（稀释后）CATYZLAB
| Q4 25 | $1.33 | $-0.05 | ||
| Q3 25 | $1.13 | $-0.03 | ||
| Q2 25 | $1.10 | $-0.04 | ||
| Q1 25 | $0.98 | $-0.04 | ||
| Q4 24 | $1.11 | $-0.09 | ||
| Q3 24 | $0.94 | $-0.04 | ||
| Q2 24 | $0.92 | $-0.08 | ||
| Q1 24 | $0.98 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $689.6M |
| 总债务越低越好 | $119.1M | — |
| 股东权益账面价值 | $2.9B | $715.5M |
| 总资产 | $24.2B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.04× | — |
8季度趋势，按日历期对齐
现金及短期投资CATYZLAB
| Q4 25 | — | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | — | $732.2M | ||
| Q1 25 | — | $757.3M | ||
| Q4 24 | — | $779.7M | ||
| Q3 24 | — | $616.1M | ||
| Q2 24 | — | $630.0M | ||
| Q1 24 | — | $650.8M |
总债务CATYZLAB
| Q4 25 | $119.1M | — | ||
| Q3 25 | $119.1M | — | ||
| Q2 25 | $119.1M | — | ||
| Q1 25 | $119.1M | — | ||
| Q4 24 | $119.1M | — | ||
| Q3 24 | $119.1M | — | ||
| Q2 24 | $119.1M | — | ||
| Q1 24 | $119.1M | — |
股东权益CATYZLAB
| Q4 25 | $2.9B | $715.5M | ||
| Q3 25 | $2.9B | $759.9M | ||
| Q2 25 | $2.9B | $791.7M | ||
| Q1 25 | $2.9B | $810.8M | ||
| Q4 24 | $2.8B | $840.9M | ||
| Q3 24 | $2.8B | $667.7M | ||
| Q2 24 | $2.8B | $704.2M | ||
| Q1 24 | $2.8B | $762.2M |
总资产CATYZLAB
| Q4 25 | $24.2B | $1.2B | ||
| Q3 25 | $24.1B | $1.2B | ||
| Q2 25 | $23.7B | $1.2B | ||
| Q1 25 | $23.2B | $1.2B | ||
| Q4 24 | $23.1B | $1.2B | ||
| Q3 24 | $23.3B | $985.3M | ||
| Q2 24 | $23.2B | $987.4M | ||
| Q1 24 | $23.4B | $988.4M |
负债/权益比CATYZLAB
| Q4 25 | 0.04× | — | ||
| Q3 25 | 0.04× | — | ||
| Q2 25 | 0.04× | — | ||
| Q1 25 | 0.04× | — | ||
| Q4 24 | 0.04× | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.04× | — | ||
| Q1 24 | 0.04× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $368.6M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $363.7M | $-26.7M |
| 自由现金流率自由现金流/营收 | 163.2% | -21.0% |
| 资本支出强度资本支出/营收 | 2.2% | 0.5% |
| 现金转化率经营现金流/净利润 | 4.07× | — |
| 过去12个月自由现金流最近4个季度 | $672.7M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流CATYZLAB
| Q4 25 | $368.6M | $-26.0M | ||
| Q3 25 | $150.6M | $-32.0M | ||
| Q2 25 | $64.0M | $-31.0M | ||
| Q1 25 | $99.0M | $-61.7M | ||
| Q4 24 | $329.2M | $-55.8M | ||
| Q3 24 | $81.2M | $-26.8M | ||
| Q2 24 | $72.9M | $-42.2M | ||
| Q1 24 | $88.2M | $-90.1M |
自由现金流CATYZLAB
| Q4 25 | $363.7M | $-26.7M | ||
| Q3 25 | $150.1M | $-35.0M | ||
| Q2 25 | $62.7M | $-33.9M | ||
| Q1 25 | $96.3M | $-63.2M | ||
| Q4 24 | $325.5M | $-58.4M | ||
| Q3 24 | $80.0M | $-28.2M | ||
| Q2 24 | $72.4M | $-42.9M | ||
| Q1 24 | $87.3M | $-91.1M |
自由现金流率CATYZLAB
| Q4 25 | 163.2% | -21.0% | ||
| Q3 25 | 71.3% | -30.4% | ||
| Q2 25 | 31.9% | -31.1% | ||
| Q1 25 | 51.2% | -59.9% | ||
| Q4 24 | 174.6% | -53.8% | ||
| Q3 24 | 42.2% | -27.7% | ||
| Q2 24 | 40.5% | -42.9% | ||
| Q1 24 | 49.8% | -104.5% |
资本支出强度CATYZLAB
| Q4 25 | 2.2% | 0.5% | ||
| Q3 25 | 0.2% | 2.6% | ||
| Q2 25 | 0.6% | 2.6% | ||
| Q1 25 | 1.4% | 1.5% | ||
| Q4 24 | 1.9% | 2.4% | ||
| Q3 24 | 0.6% | 1.3% | ||
| Q2 24 | 0.3% | 0.7% | ||
| Q1 24 | 0.5% | 1.1% |
现金转化率CATYZLAB
| Q4 25 | 4.07× | — | ||
| Q3 25 | 1.94× | — | ||
| Q2 25 | 0.83× | — | ||
| Q1 25 | 1.42× | — | ||
| Q4 24 | 4.10× | — | ||
| Q3 24 | 1.20× | — | ||
| Q2 24 | 1.09× | — | ||
| Q1 24 | 1.23× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CATY
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
